About the AACR - Leading Discoveries Magazine

Founded in 1907, the American Association for Cancer Research (AACR) is the world’s first and largest professional organization dedicated to advancing cancer research and its mission to prevent and cure cancer. AACR membership includes more than 58,000 laboratory, translational, and clinical researchers; population scientists; other health care professionals; and patient advocates residing in 141 countries and territories around the world. Presently, 34% of members live outside the United States and 20% of AACR’s international members are located in countries building cancer research capacity. The AACR marshals the full spectrum of expertise of the cancer community to accelerate progress in the prevention, diagnosis, and treatment of cancer by annually convening more than 30 conferences and educational workshops, the largest of which is the AACR Annual Meeting. The AACR publishes 10 prestigious, peer-reviewed scientific journals. Other AACR publications include Cancer Today, a magazine for cancer patients and caregivers; the annual AACR Cancer Progress Report; AACR Cancer Disparities Progress Report; AACR Annual Impact Report; Leading Discoveries, the AACR’s awareness and donor magazine; and the blog, Cancer Research Catalyst. In addition, the AACR funds meritorious research directly as well as in cooperation with numerous cancer organizations. As the Scientific Partner of Stand Up To Cancer, the AACR provides expert peer review, grants administration, and scientific oversight of team science and individual investigator grants in cancer research that have the potential for near-term patient benefit. The AACR actively communicates with legislators and other policymakers about the value of cancer research and related biomedical science in saving lives from cancer. For more information about the AACR, visit AACR.org.

AACR Officers

PRESIDENT
Lillian L. Siu, MD, FAACR (2025-2026)
Director, Phase I Clinical Trials Program, Codirector, Robert and Maggie Bras and Family Drug Development Program, Clinical Lead, Tumor Immunotherapy Program, BMO Chair, Precision Cancer Genomics, Princess Margaret Cancer Centre, Professor of Medicine, University of Toronto, Toronto, Ontario

PRESIDENT-ELECT
Keith T. Flaherty, MD, FAACR (2025-2026)
Director of Clinical Cancer Research, Richard Saltonstall Endowed Chair in Oncology, Mass General Cancer Center, Professor of Medicine, Harvard Medical School, Boston, Massachusetts, Associate Member, Broad Institute of MIT and Harvard, Cambridge, Massachusetts

IMMEDIATE PAST PRESIDENT
Patricia M. LoRusso, DO, PhD (hc), FAACR (2025-2026)
Professor of Medicine, Chief of the Early Phase Clinical Trials Program, Yale University, Associate Center Director of Experimental Therapeutics, Yale Cancer Center, New Haven, Connecticut

TREASURER
Michael A. Caligiuri, MD, FAACR (2025-2028)
Professor, Department of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Beckman Research Institute, Duarte, California

CHIEF EXECUTIVE OFFICER
Margaret Foti, PhD, MD (hc)
American Association for Cancer Research, Philadelphia, Pennsylvania

AACR Directors

John M. Carethers, MD, FAACR (2023-2026)
Vice Chancellor for Health Sciences, Professor of Medicine, University of California, San Diego, La Jolla, California

Johann S. de Bono, MD, PhD (2025-2028)
Regius Professor of Cancer Research, Professor in Experimental Cancer Medicine, Honorary Consultant Medical Oncologist, Director, Drug Development Unit, Head, Prostate Cancer Targeted Therapy Group, Institute of Cancer Research, Royal Marsden NHS Foundation Trust, London, England

Mikala Egeblad, PhD (2025-2028)
Bloomberg Distinguished Professor of Tumor Microenvironment, Member, Convergence Institute at Johns Hopkins University, Associate Director, Giovanis Institute for Translational Cell Biology, Coleader, Cancer Invasion and Metastasis Program, Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland

Manuel Hidalgo, MD, PhD, FAACR (2024-2027)
Professor of Medicine, Walter B. Wriston Professor of Pancreatic Cancer Research, Harvard Medical School, Chief, Division of Hematology and Medical Oncology, Joan and Sanford I. Weill Department of Medicine, Sandra and Edward Meyer Cancer Center, Weill Cornell Medicine, New York, New York

Christine M. Lovly, MD, PhD (2023-2026)
Associate Professor of Medicine, Division of Hematology-Oncology, Ingram Professor of Cancer Biology, Co-leader, Translational Research and Interventional Oncology Program, Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, Tennessee

Crystal L. Mackall, MD, FAACR (2025-2028)
Ernest and Amelia Gallo Family Professor, Professor of Pediatrics and of Medicine, Founding Director, Stanford Center for Cancer Cell Therapy, Director, Parker Institute for Cancer Immunotherapy at Stanford, Associate Director, Stanford Cancer Institute, Leader, Cancer Immunotherapy Program, Stanford, California

Electra D. Paskett, PhD, FAACR (2024-2027)
Marion N. Rowley Professor of Cancer Research and Director, Division of Cancer Prevention and Control, Department of Internal Medicine, Distinguished Professor, College of Medicine, Professor, Division of Epidemiology, College of Public Health, Deputy Director for Population Sciences and Community Outreach, Comprehensive Cancer Center, Founding Director, Center for Cancer Health Equity, James Cancer Hospital, The Ohio State University, Columbus, Ohio

Elizabeth A. Platz, ScD, MPH (2023-2026)
Professor and Martin D. Abeloff, MD, Scholar in Cancer Prevention, Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland

Katerina A. Politi, PhD (2024-2027)
Professor of Pathology, Co-Leader, Cancer Signaling Networks, Scientific Director, Center for Thoracic Cancers, Yale Cancer Center, New Haven, Connecticut

Charles W. M. Roberts, MD, PhD (2025-2028)
Member, St. Jude Faculty, Executive Vice President, Director, Comprehensive Cancer Center, Lillian R. Cannon Comprehensive Cancer Center Director Endowed Chair, St. Jude’s Children’s Research Hospital, Memphis, Tennessee

Alice T. Shaw, MD, PhD (2023-2026)
Chief of Strategic Partnerships, Dana-Farber Cancer Institute, Boston, Massachusetts

Jean-Charles Soria, MD, PhD (2024-2027)
Senior Vice President of Oncology, Global Development, Amgen, Thousand Oaks, California

Jedd D. Wolchok, MD, PhD, FAACR (2023-2026)
Director, Sandra and Edward Meyer Cancer Center, Professor of Medicine, Weill Cornell Medicine, New York, New York

Catherine J. Wu, MD, FAACR (2024-2027)
Professor of Medicine, Chief, Division of Stem Cell Transplantation and Cellular Therapies, Lavine Family Chair for Preventative Cancer Therapies, Dana-Farber Cancer Institute, Boston, Massachusetts

Timothy A. Yap, MBBS, PhD (2025-2028)
Ransom Horne, Jr. Endowed Professor for Cancer Research in the Department for Investigational Cancer Therapeutics (Phase I Program), Vice President and Head of Clinical Development, Therapeutics Discovery Division, Associate Director of Translational Research, Khalifa Institute for Personalized Cancer Therapy, University of Texas MD Anderson Cancer Center, Houston, Texas